Shilpa Medicare share news, announcements and annual reports
NSE: SHILPAMEDBSE: 530549Pharmaceuticals & BiotechnologySmall Cap
Shilpa Medicare Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1995 on BSE, Dec 2009 on NSE
Last close ₹955.60up ₹20.00 (2.14%)BSE ₹954.65
Share price at the NSE close on 30 Oct 2026. Previous close ₹935.60.
30 Oct: open ₹955.90, high ₹979.80, low ₹930.30
52-week range of traded prices to 30 Oct 2026
₹259.50Low, 27 Jan 2026₹1,095.00High, 1 Oct 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹18,690 Cr637th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 62.86
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹30 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 70.04
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 7.21
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.06%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.0%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹30 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 10.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 10.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.25
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,03,85439.8% delivered
Shilpa Medicare share news and announcements
752 announcements, routine notices left out, newest first. Page 12 of 16.
Nov 2017
13 Nov · Results
Oct 2017
Sep 2017
29 Sep · Meeting
Aug 2017
10 Aug · Results
Jul 2017
Jun 2017
May 2017
29 May · Results
Apr 2017
Mar 2017
28 Mar · Court Convened Meeting Updates
9 Mar · Corporate action
Feb 2017
14 Feb · Results
Jan 2017
Dec 2016
Nov 2016
25 Nov · Legal
Exchange has sought clarification from Shilpa Medicare Limited with respect to announcement dated 25-Nov-2016, regarding appointment of Mr. Rajendra Kumar Duggar, a member of ICAI and Cost Accountant as Chief Financial Officer.On basis of above the Company is required to clarify following:1. Date of appointment/cessation (as applicable) & term of appointment;2. Brief profile (in case of appointment);3. Disclosure of relationships between directors (in case of appointment of a director).The response of the Company is awaited.25 Nov · Results
3 Nov · Legal
Exchange has sought clarification from Shilpa Medicare Limited with respect to announcement dated 02-Nov-2016, regarding "Shilpa Medicare Limited has informed the Exchange that Koanna Healthcare Limited, UK, a wholly owned subsidiary of Shilpa Medicare Limited, INDIA has received marketing authorizations from the UK Medicines and Healthcare products Regulatory Agency (UK MHRA) for the IMATINIB TABLETS in multiple strengths of 100 mg and 400 mg. The marketing authorization application for this generic product is made through decentralized procedure in 15 EU member states, which involves major European countries like UK, Germany, Netherlands, France, Czech Republic, Belgium, Ireland, Romania etc. Out of 15 member states the first approval is received from UK MHRA. Approvals from remaining member states will follow. ".On basis of above the Company is required to clarify following:1. Impact/relevance of such approval/license to the listed entity;2. Period for which such approval/license is/was valid;The response of the Company is awaited.